P SPEISER
Overview
Explore the profile of P SPEISER including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
335
Citations
1122
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
SPEISER P
Dtsch Z Gesamte Gerichtl Med
. 2014 Feb;
40(4):363-7.
PMID: 24541472
No abstract available.
2.
Huttenrauch R, SPEISER P
Pharm Res
. 2013 Nov;
2(3):97-107.
PMID: 24272686
This review demonstrates that any true in vivo - in vitro correlation cannot exist. A thorough analysis of the available results shows that any attempt to qualitatively or quantitatively correlate...
3.
Chalubinski K, Pils S, Klein K, Seemann R, SPEISER P, Langer M, et al.
Ultrasound Obstet Gynecol
. 2013 Mar;
42(5):518-24.
PMID: 23471888
Objective: To evaluate whether the maximum degree of placental invasion (placenta accreta, increta or percreta) can be predicted with ultrasound imaging, using criteria developed in our department. Methods: This was...
4.
Hofstetter G, Berger A, Schuster E, Wolf A, Hager G, Vergote I, et al.
Br J Cancer
. 2011 Oct;
105(10):1593-9.
PMID: 22009029
Background: We aimed to evaluate the clinical relevance of p53 and p73 isoforms that modulate the function of p53. Methods: This prospective multicentre study included 154 patients with stage III...
5.
Rudolf M, Hochberg Z, SPEISER P
Arch Dis Child
. 2005 Sep;
90(10):994-6.
PMID: 16177153
No abstract available.
6.
Bouda J, Boudova L, Hes O, Havir M, Tempfer C, Kohlberger P, et al.
Anticancer Res
. 2005 Apr;
25(1B):617-22.
PMID: 15816636
The aim of our study was to clarify whether CD44v6 evaluation can serve as a universally applicable prognostic factor in patients with FIGO stage IB cervical carcinoma. A retrospective study...
7.
Baur M, Schernhammer E, Gneist M, Sevelda P, SPEISER P, Hudec M, et al.
Br J Cancer
. 2005 Mar;
92(6):1019-25.
PMID: 15756278
The aim of this phase I/II study was to determine the maximum tolerated dose (MTD) and the dose-limiting toxicities of chronic oral etoposide given on days 1-10 followed by rescue...
8.
Dittrich C, Sevelda P, Salzer H, Obermair A, SPEISER P, Breitenecker G, et al.
Eur J Cancer
. 2003 May;
39(8):1129-40.
PMID: 12736113
This prospective multicentre phase III trial was conducted to assess whether increased platinum dose intensity (DI) by combining carboplatin with cisplatin has an impact on overall survival (OS) and progression-free...
9.
SPEISER P
Wien Med Wochenschr
. 2002 Jan;
151(21-23):565-7.
PMID: 11762256
Acute and chronic forms of pelvic pain are symptoms of various gynaecological entities with a difficult clinical differential diagnosis. Acute pains are generally intensive attacks with a sudden onset, rapid...
10.
Pribill I, SPEISER P, Leary J, Leodolter S, Hacker N, Friedlander M, et al.
Cancer Genet Cytogenet
. 2001 Aug;
129(1):23-9.
PMID: 11520561
Progressive genetic changes such as the inactivation of tumor suppressor genes (TSG) are thought to play an important role in the initiation and progression of ovarian cancer. Frequent nonrandom allelic...